Genital warts are one of the most common sexually transmitted conditions in the world. Nearly 43% of adults aged 18 to 59 in the United States carry some form of genital HPV, the virus responsible for warts, and about 1 in 3 men globally over age 15 are infected with at least one genital HPV type. While not every HPV infection leads to visible warts, the strains that do cause them are widespread enough that most sexually active people will encounter HPV at some point in their lives.
HPV Infection vs. Genital Warts
It helps to separate two things: carrying HPV and actually developing warts. HPV is extremely common. CDC data from 2013 to 2014 found that 45.2% of men and 39.9% of women aged 18 to 59 tested positive for at least one genital HPV type. Most of these infections cause no symptoms at all and clear on their own within one to two years as the immune system suppresses the virus.
Genital warts specifically are caused by low-risk HPV types 6 and 11, which account for about 90% of all wart cases. These strains are distinct from the high-risk types (like HPV-16 and HPV-18) linked to cancers. Globally, HPV-6 is the second most common genital HPV type in men, found in roughly 4% of those tested. So while tens of millions of people carry wart-causing strains, only a fraction develop visible growths.
Who Gets Genital Warts Most Often
Genital warts peak in young adults. The highest rates appear in people in their late teens through mid-twenties, which tracks with the age range where new sexual partnerships are most frequent. Men are slightly more likely than women to carry genital HPV overall (45.2% vs. 39.9%), and HPV in men tends to show up clinically as warts more often than in women, where infections are more likely to remain invisible.
Risk increases with the number of sexual partners, inconsistent condom use, and a weakened immune system. People who are immunocompromised, whether from medication or an underlying condition, are more likely to develop warts and to have them persist or recur after treatment.
How Vaccination Has Changed the Numbers
The HPV vaccine has dramatically reduced genital wart rates in countries with strong vaccination programs. Among vaccinated teen girls in the United States, infections with the HPV types that cause most warts and HPV-related cancers have dropped 88%. Among young adult women, that reduction is 81%. These numbers reflect real-world impact, not just clinical trial results.
Countries like Australia, which introduced school-based HPV vaccination early and achieved high coverage, have seen genital wart diagnoses in young people fall to near zero in vaccinated age groups. The effect extends beyond vaccinated individuals: when enough people in a population are vaccinated, unvaccinated people benefit too because there are fewer carriers to transmit the virus. This herd protection effect has been documented in several national vaccination programs.
Recurrence After Treatment
One reason genital warts feel so common is that they frequently come back. Treatment removes visible warts but does not eliminate the underlying HPV infection. The recurrence rate sits around 30 to 35%, and at least 20% of recurrences happen within the first 12 weeks after treatment. This means roughly one in three people who clear their warts will see them return, sometimes in the same spot, sometimes nearby.
Recurrence is more likely in people with larger or more numerous warts at first diagnosis, those who smoke, and those with weakened immune systems. Over time, though, most people’s immune systems gain enough control over the virus that outbreaks stop. The majority of HPV infections, including wart-causing types, become undetectable within two years without any treatment at all.
Putting the Numbers in Perspective
Genital warts are common enough that they carry no particular stigma in clinical settings. Doctors and sexual health clinics see them routinely. The condition is not dangerous in the medical sense: HPV types 6 and 11 are classified as “nononcogenic,” meaning they do not cause cancer. The concern is cosmetic, the discomfort they can cause, and the ease with which they spread to partners.
If you’re under 26 and haven’t been vaccinated, the HPV vaccine covers types 6 and 11 along with cancer-causing strains, making it the single most effective way to avoid genital warts entirely. For those between 27 and 45, vaccination can still offer benefit depending on prior exposure. The vaccine works best before any contact with the virus, which is why it’s recommended starting at age 11 or 12, but catching up later still provides meaningful protection against strains you haven’t yet encountered.